Cite
HARVARD Citation
Shaw, L. et al. (n.d.). [P4–155]: DERIVING A CUT‐OFF FOR THE ELECSYS® β‐AMYLOID (1–42) IMMUNOASSAY FOR USE IN CLINICAL TRIALS SUPPORTED BY ELI LILLY FOR PATIENTS WITH CLINICALLY DEFINED ALZHEIMER's DISEASE (AD). Alzheimer's & dementia. pp. P1317-P1318. [Online].